Our previously funded proposal was directed at testing the suitability of the purified human cell DNA synthesome as an in vitro model system for defining the mechanism of action of anticancer drugs by comparing it to well studied cell-based model systems. Much of our work was performed using three anticancer drugs with known structure-function activities; namely, camptothecin (CPT), ara-C and etoposide (VP16). The results of our studies strongly suggest that the DNA synthesome has the ability to interact with these agents as observed in intact cells. Therefore, in this application it is our intention to fully develop, and demonstrate the utility of, the purified human cell DNA synthesome as an in vitro model system for investigating the action of anticancer drugs by: (1) directly verifying that the in vitro interaction of the synthesome with anticancer agents known to affect DNA replication are representative of the molecular events occurring in the intact cell. This will be accomplished by analyzing the types of daughter DNA molecules produced by the complex, in DNA replication reactions performed in the presence and absence of these drugs using high resolution electrophoresis (HRE). The results will be compared with the DNA replication intermediates isolated from cells exposed to these same agents. (2) We will also perform detailed studies on the action of anticancer agents at the synthesome DNA replication fork by: (a) determining the effect of CPT, VP16 and ara-C and VP16 on their synthesome associated target-proteins; (c) determining the ability of ara-C to affect the coordinated synthesis of DNA by the synthesome; and (d) investigating the incorporation of ara-CMP by the synthesome into DNA at internucleotide linkages. (3) In addition, we propose studies to determine some of the biological consequences of internucleootide ara-CMP residues incorporated into DNA by the DNA synthesome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA057350-04A1
Application #
2008095
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1993-05-01
Project End
1999-11-30
Budget Start
1997-02-10
Budget End
1997-11-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Dai, Heqiao; Liu, Jianying; Malkas, Linda H et al. (2009) Characterization of RNA primers synthesized by the human breast cancer cell DNA synthesome. J Cell Biochem 106:798-811
Dai, Heqiao; Liu, Jianying; Malkas, Linda H et al. (2009) Chromium reduces the in vitro activity and fidelity of DNA replication mediated by the human cell DNA synthesome. Toxicol Appl Pharmacol 236:154-65
Sandoval, John A; Turner, Katharyn E; Hoelz, Derek J et al. (2007) Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. J Surg Res 142:268-74
Sandoval, John A; Grosfeld, Jay L; Hickey, Robert J et al. (2006) Structural analysis of the human neuroblastoma DNA replication complex: insights into faulty proliferation. J Pediatr Surg 41:266-70
Sandoval, John A; Dobrolecki, Lacey E; Huang, Jeffrey et al. (2006) Neuroblastoma detection using serum proteomic profiling: a novel mining technique for cancer? J Pediatr Surg 41:639-46; discussion 639-46
Sandoval, John A; Hoelz, Derek J; Woodruff, Heather A et al. (2006) Novel peptides secreted from human neuroblastoma: useful clinical tools? J Pediatr Surg 41:245-51
Escobar, Mauricio A; Hoelz, Derek J; Sandoval, John A et al. (2005) Profiling of nuclear extract proteins from human neuroblastoma cell lines: the search for fingerprints. J Pediatr Surg 40:349-58
Sandoval, John A; Hickey, Robert J; Malkas, Linda H (2005) Isolation and characterization of a DNA synthesome from a neuroblastoma cell line. J Pediatr Surg 40:1070-7
Yang, Jin; Chen, Zhiwen; Liu, Yang et al. (2004) Altered DNA polymerase iota expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis. Cancer Res 64:5597-607
Abdel-Aziz, Waleed; Hickey, Robert J; Malkas, Linda H (2004) An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents. Biochem Pharmacol 68:11-21

Showing the most recent 10 out of 27 publications